Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
10:41pm, Wednesday, 24'th Feb 2021
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pri
Why Halozyme Therapeutics Is Trading 14% Higher Today
03:39pm, Wednesday, 24'th Feb 2021
Investors liked what they saw in the company's fourth-quarter earnings release.
Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls
09:53am, Wednesday, 24'th Feb 2021
Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates.
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q4 2020 Results - Earnings Call Transcript
09:55pm, Tuesday, 23'rd Feb 2021
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q4 2020 Results - Earnings Call Transcript
Recap: Halozyme Therapeutics Q4 Earnings
04:31pm, Tuesday, 23'rd Feb 2021
Shares of Halozyme Therapeutics (NASDAQ:HALO) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 308.33% over the past year to $0.50
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
04:10pm, Tuesday, 23'rd Feb 2021
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it
Halozyme: Nice Pivot To A Royalty Business
12:46pm, Tuesday, 23'rd Feb 2021
Halozyme: Nice Pivot To A Royalty Business
Halozyme Therapeutics's Earnings: A Preview
10:07am, Monday, 22'nd Feb 2021
Halozyme Therapeutics (NASDAQ:HALO) releases its next round of earnings this Tuesday, February 23. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
SAN DIEGO, Jan. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) has received U.S. Food and Drug Administration (FDA) approval o
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
12:02pm, Wednesday, 13'th Jan 2021
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
3 Biotech Stocks Worth Adding to Your Portfolio in 2021
09:47am, Friday, 08'th Jan 2021
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
SAN DIEGO, Dec. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission has approved Roche's Phesgo®, a fixed-dose combination of Perjeta® (p
5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic
12:47pm, Friday, 18'th Dec 2020
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popu
Halozyme: 7 Years Of Royalty Bliss Coming; Afterwards, Questions To Answer
10:41pm, Sunday, 06'th Dec 2020
Halozyme has settled into its role as a royalty cash machine after transitioning away from a drug discovery company, and the immediate future looks very bright. With 5 products currently on the market
What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now?
12:00pm, Friday, 27'th Nov 2020
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
